M&A Deal Summary

Life Technologies Acquires Compendia Bioscience

On October 8, 2012, Life Technologies acquired life science company Compendia Bioscience

Acquisition Highlights
  • This is Life Technologies’ 6th transaction in the Life Science sector.
  • This is Life Technologies’ 13th transaction in the United States.
  • This is Life Technologies’ 1st transaction in Michigan.

M&A Deal Summary
Date 2012-10-08
Target Compendia Bioscience
Sector Life Science
Buyer(s) Life Technologies
Deal Type Add-on Acquisition

Target

Compendia Bioscience

Ann Arbor, Michigan, United States
Compendia Bioscience, Inc. is a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Life Technologies

Carlsbad, California, United States
Category Company
Sector Test/Measurement Equipment
Employees10,000
Revenue 3.8B USD (2012)
DESCRIPTION

Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum – scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research.

DEAL STATS #
Overall 15 of 16
Sector (Life Science) 6 of 7
Type (Add-on Acquisition) 12 of 13
State (Michigan) 1 of 1
Country (United States) 13 of 13
Year (2012) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-07-25 Pinpoint Genomics

Mountain View, California, United States

Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer test that can help doctors identify those early-stage patients at high risk for progression to late-stage disease.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-22 BAC BV

Naarden, Netherlands

BAC BV discovers, develops and manufactures separation and affinity purification products for use across the value chain of biopharmaceutical R&D and manufacturing.

Buy -
Mergr

Product

Company

Legal